One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
AIDS Vaccine Science for Busy Advocates – RV144: Building on a breakthrough
A one-page document describing RV144, the first AIDS vaccine trial to show protection against HIV in humans, and plans to further this research.
HIV Vaccines: Key messages
This is a three-page document providing main points surrounding vaccine research. For a shorter one-page version of this, click here.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Thai)
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Russian)
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Portuguese)
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
Community Stakeholder Checklist
The Community Stakeholder Checklist is a set of questions that can be used by community stakeholders to evaluate a research team’s compliance with the Good Participatory Practice guidelines. The checklist can be used as a starting point for dialogue with a research team, a way to share experiences with other stakeholders or as an assessment tool.
Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.
2013 AVAC Report: Research and Reality
Research & Reality calls on funders and researchers to capitalize on lessons learned from a range of recent HIV prevention trials via better problem solving, more critical thinking and coordinated action. This year’s AVAC Report identifies progress and gaps in large-scale human trials, rollout of proven options and ongoing research for new advances that women and men will want to use.
2012 AVAC Report: Achieving the End—One Year and Counting
AVAC Report 2012, Achieving the End—One Year and Counting, sets a clock on the global drive to end the AIDS epidemic. The past twelve months have seen remarkable global consensus that it is possible to begin to end the epidemic. The same time period has seen concepts like “combination prevention” and “treatment as prevention” capture the world’s attention. But without specific interim goals—and far more precision about what combination prevention and other key concepts mean—the lofty goal of ending the epidemic will not be achieved.